{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:28:40Z","timestamp":1793521720263,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.esmoop.2025.105846","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T22:50:18Z","timestamp":1759877418000},"page":"105846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Critical insights on real-life PD-L1 histopathological workflow and assessment in esophageal, esophagogastric junction, and gastric carcinoma in Italy"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7826-002X","authenticated-orcid":false,"given":"A.","family":"Gambella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Grillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0591-6723","authenticated-orcid":false,"given":"P.","family":"Parente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vanoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5139-3869","authenticated-orcid":false,"given":"A.","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4188-4247","authenticated-orcid":false,"given":"M.","family":"Paudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Angerilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3890-8757","authenticated-orcid":false,"given":"F.","family":"Castri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4207-3665","authenticated-orcid":false,"given":"A.","family":"Pastorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6515-5482","authenticated-orcid":false,"given":"M.","family":"Fassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0193-5281","authenticated-orcid":false,"given":"L.","family":"Mastracci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Albarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Aprile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Banchelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Barresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.R.","family":"Billo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cassoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Cerbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"D\u2019Armiento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"De Lisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.C.","family":"Falco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Fiorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fortunato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"La Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Locci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Macciomei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Melocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Morbini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Nardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Panarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.G.","family":"Pozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Remo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Savino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Spaggiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Sommavilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2025.105846_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105846_bib2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00000658-199810000-00002","article-title":"Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study","volume":"228","author":"Siewert","year":"1998","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105846_bib3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/00000658-200110000-00011","article-title":"Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies","volume":"234","author":"Hagen","year":"2001","journal-title":"Ann Surg"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105846_bib4","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1016\/j.ejca.2013.05.029","article-title":"Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data","volume":"49","author":"Ronellenfitsch","year":"2013","journal-title":"Eur J Cancer"},{"issue":"10111","key":"10.1016\/j.esmoop.2025.105846_bib5","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105846_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10294","key":"10.1016\/j.esmoop.2025.105846_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"10302","key":"10.1016\/j.esmoop.2025.105846_bib8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105846_bib9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.annonc.2023.01.006","article-title":"VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G\/GEJ) cancer: phase III KEYNOTE-859 study","volume":"34","author":"Rha","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105846_bib10","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105846_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105846_bib12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00428-024-04005-1","article-title":"The role of the pathologist in the design and conducting of biomarker-driven clinical trials in cancer: position paper of the European Society of Pathology","volume":"486","author":"Matias-Guiu","year":"2025","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105846_bib13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.32074\/1591-951X-836","article-title":"A practical approach for PD-L1 evaluation in gastroesophageal cancer","volume":"115","author":"Angerilli","year":"2023","journal-title":"Pathologica"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105846_bib14","doi-asserted-by":"crossref","first-page":"352","DOI":"10.32074\/1591-951X-803","article-title":"PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application","volume":"114","author":"Mastracci","year":"2022","journal-title":"Pathologica"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105846_bib15","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/14737159.2023.2288267","article-title":"A charming molecular profile in the wrong tissue: the pathologist in the era of molecular diagnostics in the gastrointestinal tract","volume":"23","author":"Parente","year":"2023","journal-title":"Expert Rev Mol Diagn"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105846_bib16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.32074\/1591-951X-158","article-title":"Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice","volume":"112","author":"Fassan","year":"2020","journal-title":"Pathologica"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105846_bib17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105846_bib18","article-title":"The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci Rep"},{"issue":"7528","key":"10.1016\/j.esmoop.2025.105846_bib19","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"7528","key":"10.1016\/j.esmoop.2025.105846_bib20","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105846_bib21","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1200\/JCO.2024.42.16_suppl.2633","article-title":"AI based PD-L1 CPS quantifier software to identify more patients for checkpoint therapy in gastric cancer at pathologist-level interobserver concordance","volume":"42","author":"Badve","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105846_bib22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00428-019-02653-2","article-title":"PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation","volume":"476","author":"Kim","year":"2020","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105846_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40644-025-00855-3","article-title":"An interpretable machine learning model based on computed tomography radiomics for predicting programmed death ligand 1 expression status in gastric cancer","volume":"25","author":"Dai","year":"2025","journal-title":"Cancer Imaging"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105846_bib24","doi-asserted-by":"crossref","first-page":"e13553","DOI":"10.1200\/JCO.2023.41.16_suppl.e13553","article-title":"Performance validation of an artificial intelligence-powered PD-L1 combined positive score analyzer in six cancer types","volume":"41","author":"Lee","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105846_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.156068","article-title":"Immunohistochemical biomarker scoring in gastroesophageal cancers: can computers help us?","volume":"272","author":"Caputo","year":"2025","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.esmoop.2025.105846_bib26","article-title":"PD-L1 immunohistochemistry in gastric cancer: comparison of combined positive score and tumor area positivity across 28-8, 22C3, and SP263 assays","volume":"8","author":"Klempner","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105846_bib27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13000-023-01318-8","article-title":"Tumor area positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring","volume":"18","author":"Liu","year":"2023","journal-title":"Diagn Pathol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105846_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103962","article-title":"Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups","volume":"9","author":"Leone","year":"2024","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105846_bib29","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10418","key":"10.1016\/j.esmoop.2025.105846_bib30","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2025.105846_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105846_bib32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"issue":"35","key":"10.1016\/j.esmoop.2025.105846_bib33","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105846_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7235","article-title":"Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial","volume":"13","author":"Kato","year":"2024","journal-title":"Cancer Med"},{"issue":"26","key":"10.1016\/j.esmoop.2025.105846_bib35","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.21.01926","article-title":"Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study","volume":"40","author":"Shen","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105846_bib36","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study","volume":"24","author":"Xu","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.105846_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155145","article-title":"Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: a literature review with expert opinion","volume":"254","author":"Angerilli","year":"2024","journal-title":"Pathol Res Pract"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105846_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70280","article-title":"Population PK and exposure-response analyses of zolbetuximab in patients with locally advanced unresectable or metastatic G\/GEJ adenocarcinoma","volume":"18","author":"Yamada","year":"2025","journal-title":"Clin Transl Sci"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105846_bib39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric cancer, version 2.2025, NCCN Clinical Practice Guidelines In Oncology","volume":"23","author":"Ajani","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105846_bib40","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s10120-024-01571-w","article-title":"Nationwide survey on HER2 and PD-L1 testing practices in gastric cancer across Japan","volume":"28","author":"Abe","year":"2025","journal-title":"Gastric Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105846_bib41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00418-017-1558-4","article-title":"Section detachment in immunohistochemistry: causes, troubleshooting, and problem-solving","volume":"148","author":"Gambella","year":"2017","journal-title":"Histochem Cell Biol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105846_bib42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00418-015-1316-4","article-title":"Factors affecting immunoreactivity in long-term storage of formalin-fixed paraffin-embedded tissue sections","volume":"144","author":"Grillo","year":"2015","journal-title":"Histochem Cell Biol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105846_bib43","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/PAI.0000000000001153","article-title":"Impact of prolonged ischemia on the immunohistochemical expression of programmed death ligand 1 (PD-L1)","volume":"31","author":"Barbera","year":"2023","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105846_bib44","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/PAI.0000000000000847","article-title":"The immunohistochemical expression of programmed death ligand 1 (PD-L1) is affected by sample overfixation","volume":"29","author":"Barbera","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105846_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100220","article-title":"Impact of decalcification, cold ischemia, and deglycosylation on performance of programmed cell death ligand-1 antibodies with different binding epitopes: comparison of 7 clones","volume":"36","author":"Lawson","year":"2023","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105846_bib46","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00418-017-1596-y","article-title":"Quality control in diagnostic immunohistochemistry: integrated on-slide positive controls","volume":"148","author":"Bragoni","year":"2017","journal-title":"Histochem Cell Biol"},{"issue":"21","key":"10.1016\/j.esmoop.2025.105846_bib47","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105846_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104134","article-title":"ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma","volume":"10","author":"Obermannova","year":"2025","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105846_bib49","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/s41379-021-00823-9","article-title":"PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy","volume":"34","author":"Ahn","year":"2021","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105846_bib50","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4143\/crt.2019.718","article-title":"PD-L1 testing in gastric cancer by the combined positive score of the 22C3 pharmDx and SP263 assay with clinically relevant cut-offs","volume":"52","author":"Park","year":"2020","journal-title":"Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105846_bib51","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"ESMO Gastric Cancer Living Guideline v1.4. 2024","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105846_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103967","article-title":"PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. a systematic review and meta-analysis of seven phase III randomized trials","volume":"9","author":"Formica","year":"2024","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105846_bib53","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"issue":"10389","key":"10.1016\/j.esmoop.2025.105846_bib54","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105846_bib55","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s10120-024-01466-w","article-title":"Bemarituzumab as first-line treatment for locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial","volume":"27","author":"Wainberg","year":"2024","journal-title":"Gastric Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:13:22Z","timestamp":1773159202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2059702925017156"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105846","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Critical insights on real-life PD-L1 histopathological workflow and assessment in esophageal, esophagogastric junction, and gastric carcinoma in Italy","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105846","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105846"}}